{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T11:39:57Z","timestamp":1792409997191,"version":"4.4.0"},"reference-count":68,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Ther Med"],"DOI":"10.3892\/etm.2021.11037","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T13:01:52Z","timestamp":1638536512000},"source":"Crossref","is-referenced-by-count":58,"title":["Tyrosine kinase inhibitors in breast cancer (Review)"],"prefix":"10.3892","volume":"23","author":[{"given":"George","family":"Iancu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Faculty of Medicine, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragos","family":"Serban","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Faculty of Medicine, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristinel","family":"Badiu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Faculty of Medicine, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tanasescu","sequence":"additional","affiliation":[{"name":"Third Clinico\u2011Surgical Department, Faculty of Medicine, \u2018Lucian Blaga\u2019 University, 550169 Sibiu, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai","family":"Tudosie","sequence":"additional","affiliation":[{"name":"Department of Orthopedia and Intensive care, Faculty of Medicine, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corneliu","family":"Tudor","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Faculty of Medicine, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Costea","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Faculty of Medicine, \u2018Ovidius\u2019 University, 900470 Constanta, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Zgura","sequence":"additional","affiliation":[{"name":"Department of Oncology Radiotherapy, Institute of Oncology \u2018Prof. Dr. Trestioreanu\u2019, 022328 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Iancu","sequence":"additional","affiliation":[{"name":"Department of ENT\u2011Opthalmology, Faculty of Medicine, Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danut","family":"Vasile","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Faculty of Medicine, \u2018Carol Davila\u2019 University of Medicine and Pharmacy, 020021 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2021,12,3]]},"reference":[{"key":"key20220302121929_b1-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1200\/JCO.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20220302121929_b2-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1677\/erc.1.00600","article-title":"Epidermal growth factor receptor inhibition strategies in oncology","volume":"11","author":"Harari","year":"2004","journal-title":"Endocr Relat Cancer"},{"key":"key20220302121929_b3-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: Its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene"},{"issue":"2081, 2081","key":"key20220302121929_b4-ETM-0-0-11037","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082081","article-title":"The changing paradigm for the treatment of HER2-positive breast cancer","volume":"12","author":"Patel","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20220302121929_b5-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2174\/1574887112666170202165049","article-title":"Neoadjuvant therapy for HER2-positive breast cancer","volume":"12","author":"Wuerstlein","year":"2017","journal-title":"Rev Recent Clin Trials"},{"key":"key20220302121929_b6-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","article-title":"Triple negative tumors: A critical review","volume":"52","author":"Reis-Filho","year":"2008","journal-title":"Histopathology"},{"key":"key20220302121929_b7-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.14670\/HH-27.1481","article-title":"Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers","volume":"27","author":"Choi","year":"2012","journal-title":"Histol Histopathol"},{"key":"key20220302121929_b8-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"785","DOI":"10.14670\/HH-27.785","article-title":"Molecular characterization of EGFR and EGFR-downstream pathways in triple negative breast carcinomas with basal like features","volume":"27","author":"Martin","year":"2012","journal-title":"Histol Histopathol"},{"issue":"1249","key":"key20220302121929_b9-ETM-0-0-11037","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01249","article-title":"The latest battles between EGFR monoclonal antibodies and resistant tumor cells","volume":"10","author":"Cai","year":"2020","journal-title":"Front Oncol"},{"key":"key20220302121929_b10-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cncr.22381","article-title":"Prognostic markers in triple-negative breast cancer","volume":"109","author":"Rakha","year":"2007","journal-title":"Cancer"},{"key":"key20220302121929_b11-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41416-021-01519-2","article-title":"Coregulation of pathways in lung cancer patients with EGFR mutation: Therapeutic opportunities","author":"Rosell","year":"2021","journal-title":"Br J Cancer"},{"key":"key20220302121929_b12-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5306\/wjco.v2.i2.80","article-title":"Tyrosine kinase inhibitors: Multi-targeted or single-targeted?","volume":"2","author":"Broekman","year":"2011","journal-title":"World J Clin Oncol"},{"key":"key20220302121929_b13-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1159\/000443368","article-title":"Drug resistance to EGFR inhibitors in lung cancer","volume":"61","author":"Tetsu","year":"2016","journal-title":"Chemotherapy"},{"key":"key20220302121929_b14-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1159\/000446361","article-title":"Mutant p53 gain of function and chemoresistance: The role of mutant p53 in response to clinical chemotherapy","volume":"62","author":"He","year":"2017","journal-title":"Chemotherapy"},{"key":"key20220302121929_b15-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1200\/JCO.2005.08.326","article-title":"Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20220302121929_b16-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1093\/annonc\/mdp202","article-title":"Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer","volume":"20","author":"Green","year":"2009","journal-title":"Ann Oncol"},{"key":"key20220302121929_b17-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"3816","DOI":"10.1200\/JCO.2006.09.6578","article-title":"A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer","volume":"25","author":"Smith","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20220302121929_b18-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S1470-2045(05)70176-5","article-title":"Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: A double-blind placebo-controlled phase II randomised trial","volume":"6","author":"Polychronis","year":"2005","journal-title":"Lancet Oncol"},{"key":"key20220302121929_b19-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1904","DOI":"10.1158\/1078-0432.CCR-09-2282","article-title":"Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer","volume":"16","author":"Cristofanilli","year":"2010","journal-title":"Clin Cancer Res"},{"key":"key20220302121929_b20-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s10549-012-1997-5","article-title":"A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer","volume":"133","author":"Carlson","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"key20220302121929_b21-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s10549-011-1352-2","article-title":"Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial","volume":"126","author":"Bernsdorf","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"key20220302121929_b22-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.ejca.2015.10.012","article-title":"A European organisation for research and treatment of cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)","volume":"53","author":"Tryfonidis","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20220302121929_b23-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s10549-008-0055-9","article-title":"Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer","volume":"115","author":"Dickler","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"key20220302121929_b24-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"10503","DOI":"10.18632\/oncotarget.2391","article-title":"Metformin and erlotinib synergize to inhibit basal breast cancer","volume":"5","author":"Lau","year":"2014","journal-title":"Oncotarget"},{"key":"key20220302121929_b25-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"324","DOI":"10.7150\/jca.2.324","article-title":"Targeting EGFR in triple negative breast cancer","volume":"2","author":"Ueno","year":"2011","journal-title":"J Cancer"},{"key":"key20220302121929_b26-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1200\/JCO.2007.13.5939","article-title":"Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers","volume":"26","author":"Guix","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20220302121929_b27-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/S1470-2045(15)00540-9","article-title":"Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): An open-label, randomised, phase 3 trial","volume":"17","author":"Harbeck","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20220302121929_b28-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S1470-2045(15)00373-3","article-title":"Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): A randomised, open-label, multicentre, phase 2 trial","volume":"16","author":"Cort\u00e9s","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20220302121929_b29-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1159\/000454727","article-title":"Clinical efficacy of afatinib treatment for a patient with leptomeningeal carcinomatosis","volume":"62","author":"Kawaguchi","year":"2017","journal-title":"Chemotherapy"},{"key":"key20220302121929_b30-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1158\/1078-0432.CCR-14-2774","article-title":"Dual blockade with afatinib and trastuzumab as NEoadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy-DAFNE (GBG-70)","volume":"21","author":"Hanusch","year":"2015","journal-title":"Clin Cancer Res"},{"key":"key20220302121929_b31-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.2147\/OTT.S106055","article-title":"The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: A randomized meta-analysis","volume":"9","author":"Chen","year":"2016","journal-title":"Onco Targets Ther"},{"key":"key20220302121929_b32-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/S0140-6736(11)61847-3","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): A randomised, open-label, multicentre, phase 3 trial","volume":"379","author":"Baselga","year":"2012","journal-title":"Lancet"},{"key":"key20220302121929_b33-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/S1470-2045(14)70320-1","article-title":"Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): Survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response","volume":"15","author":"de Azambuja","year":"2014","journal-title":"Lancet Oncol"},{"key":"key20220302121929_b34-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/annonc\/mdu551","article-title":"Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: Results of the randomised phase II EORTC 10054 study","volume":"26","author":"Bonnefoi","year":"2015","journal-title":"Ann Oncol"},{"key":"key20220302121929_b35-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1200\/JCO.2015.62.1797","article-title":"Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: Results from the randomized phase III adjuvant lapatinib and\/or trastuzumab treatment optimization trial","volume":"34","author":"Piccart-Gebhart","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20220302121929_b36-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1056\/NEJMoa064320","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer","year":"2006","journal-title":"N Engl J Med"},{"key":"key20220302121929_b37-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1634\/theoncologist.2009-0240","article-title":"Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer","volume":"15","author":"Schwartzberg","year":"2010","journal-title":"Oncologist"},{"key":"key20220302121929_b38-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1634\/theoncologist.2010-0012","article-title":"Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib","volume":"15","author":"Sherrill","year":"2010","journal-title":"Oncologist"},{"key":"key20220302121929_b39-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"5538","DOI":"10.1200\/JCO.2009.23.3734","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20220302121929_b40-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1200\/JCO.2008.21.4437","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20220302121929_b41-ETM-0-0-11037"},{"key":"key20220302121929_b42-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1038\/bjc.2013.178","article-title":"Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer","volume":"108","author":"Chow","year":"2013","journal-title":"Br J Cancer"},{"key":"key20220302121929_b43-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(15)00551-3","article-title":"Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"17","author":"Chan","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20220302121929_b44-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1007\/s00280-009-0975-z","article-title":"A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer","volume":"64","author":"Rixe","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"key20220302121929_b45-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S1470-2045(18)30256-0","article-title":"Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: A non-randomised, open-label, phase 1b study","volume":"19","author":"Murthy","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20220302121929_b46-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","article-title":"Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer","volume":"382","author":"Murthy","year":"2020","journal-title":"N Engl J Med"},{"key":"key20220302121929_b47-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.2016.69.6179","article-title":"Phase I study and biomarker analysis of pyrotinib, a novel irreversible pan-ErbB receptor tyrosine kinase inhibitor, in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer","volume":"35","author":"Ma","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20220302121929_b48-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.canlet.2019.01.005","article-title":"CDK4\/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer","volume":"447","author":"Zhang","year":"2019","journal-title":"Cancer Lett"},{"key":"key20220302121929_b49-ETM-0-0-11037","first-page":"2103","article-title":"Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer","volume":"9","author":"Xuhong","year":"2019","journal-title":"Am J Cancer Res"},{"key":"key20220302121929_b50-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1200\/JCO.19.00108","article-title":"Pyrotinib or lapatinib combined with capecitabine in HER2-positive metastatic breast cancer with prior taxanes, anthracyclines, and\/or trastuzumab: A randomized, phase II study","volume":"37","author":"Ma","year":"2019","journal-title":"J Clin Oncol"},{"issue":"S1001","key":"key20220302121929_b51-ETM-0-0-11037","article-title":"Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study","volume":"37 (Suppl 15)","author":"Jiang","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20220302121929_b52-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"8749","DOI":"10.2147\/OTT.S252117","article-title":"Pathological complete response from pyrotinib combined with trastuzumab, paclitaxel and cisplatin in a postpartum woman with HER2-positive locally advanced breast cancer: A case report","volume":"13","author":"He","year":"2020","journal-title":"Onco Targets Ther"},{"issue":"653","key":"key20220302121929_b53-ETM-0-0-11037","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07143-2","article-title":"Pyrotinib with trastuzumab and aromatase inhibitors as first-line treatment for HER2 positive and hormone receptor positive metastatic or locally advanced breast cancer: Study protocol of a randomized controlled trial","volume":"20","author":"Wang","year":"2020","journal-title":"BMC Cancer"},{"key":"key20220302121929_b54-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1093\/jnci\/djr293","article-title":"Avastin hearing leads to more uncertainty over drug's future","volume":"103","author":"Goozner","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"key20220302121929_b55-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cnur.2016.11.005","article-title":"Dermatologic reactions to targeted therapy: A focus on epidermal growth factor receptor inhibitors and nursing care","volume":"52","author":"Barton-Burke","year":"2017","journal-title":"Nurs Clin North Am"},{"issue":"238","key":"key20220302121929_b56-ETM-0-0-11037","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2014.00238","article-title":"Management of common toxicities in metastatic NSCLC related to anti-lung cancer therapies with EGFR-TKIs","volume":"4","author":"Melosky","year":"2014","journal-title":"Front Oncol"},{"key":"key20220302121929_b57-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","article-title":"Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies","volume":"13","author":"Wacker","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"e46614","key":"key20220302121929_b58-ETM-0-0-11037","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046614","article-title":"Synthetic lethal interactions between EGFR and PARP inhibition in human triple negative breast cancer cells","volume":"7","author":"Nowsheen","year":"2012","journal-title":"PLoS One"},{"key":"key20220302121929_b59-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1016\/j.ejca.2014.07.004","article-title":"Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer","volume":"50","author":"Garc\u00eda-Parra","year":"2014","journal-title":"Eur J Cancer"},{"key":"key20220302121929_b60-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"key20220302121929_b61-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Stagg","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20220302121929_b62-ETM-0-0-11037","first-page":"520","article-title":"HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors","volume":"8","author":"M\u00e9nard","year":"2002","journal-title":"Clin Cancer Res"},{"key":"key20220302121929_b63-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: Clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20220302121929_b64-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/35077232","article-title":"Genome maintenance mechanisms for preventing cancer","volume":"411","author":"Hoeijmakers","year":"2001","journal-title":"Nature"},{"key":"key20220302121929_b65-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/j.cell.2012.03.031","article-title":"Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks","volume":"149","author":"Lee","year":"2012","journal-title":"Cell"},{"key":"key20220302121929_b66-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1093\/annonc\/mdq345","article-title":"International expert panel on inflammatory breast cancer: Consensus statement for standardized diagnosis and treatment","volume":"22","author":"Dawood","year":"2011","journal-title":"Ann Oncol"},{"issue":"R9","key":"key20220302121929_b67-ETM-0-0-11037","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2225","article-title":"Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): Analysis of 2,014 IBC patient cases from the California cancer registry","volume":"11","author":"Zell","year":"2009","journal-title":"Breast Cancer Res"},{"key":"key20220302121929_b68-ETM-0-0-11037","doi-asserted-by":"publisher","first-page":"869","DOI":"10.3892\/ijo.2015.3306","article-title":"Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review)","volume":"48","author":"Nitulescu","year":"2016","journal-title":"Int J Oncol"}],"container-title":["Experimental and Therapeutic Medicine"],"original-title":[],"deposited":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T10:21:06Z","timestamp":1646216466000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/etm.2021.11037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,3]]},"references-count":68,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,12,3]]}},"URL":"https:\/\/doi.org\/10.3892\/etm.2021.11037","relation":{},"ISSN":["1792-0981","1792-1015"],"issn-type":[{"value":"1792-0981","type":"print"},{"value":"1792-1015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,3]]},"article-number":"114"}}